Shattuck Labs Stock (NASDAQ:STTK)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.28

52W Range

$1.15 - $11.76

50D Avg

$3.45

200D Avg

$6.87

Market Cap

$58.23M

Avg Vol (3M)

$483.73K

Beta

1.73

Div Yield

-

STTK Company Profile


Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

Oct 09, 2020

Website

STTK Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Mar 24
License$1.50M$800.00K

Fiscal year ends in Dec 23 | Currency in USD

STTK Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.66M$652.00K$30.02M
Operating Income$-91.96M$-103.33M$-45.27M
Net Income$-87.30M$-100.56M$-44.35M
EBITDA$-91.96M$-103.33M$-43.89M
Basic EPS-$-2.37$-1.06
Diluted EPS-$-2.37$-1.06

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 23Nov 10, 23 | 2:45 PM
Q4 22Feb 26, 23 | 10:53 AM
Q3 22Nov 12, 22 | 6:47 AM

Peer Comparison


TickerCompany
NRIXNurix Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
KYMRKymera Therapeutics, Inc.
PRLDPrelude Therapeutics Incorporated
FHTXFoghorn Therapeutics Inc.
STOKStoke Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
CSBRChampions Oncology, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
PRDSPardes Biosciences, Inc.
ELYMEliem Therapeutics, Inc.